SFRP1 and prostate carcinoma: In addition, Song et al.47 confirmed that mIR-1301-3p targeted Wnt pathway inhibitors Gsk3β and SFRP1, and promoted the proliferation of prostate cancer stem cells by inhibiting sFRP1 and GSK3β and activating Wnt/β-catenin pathway.